SEC EDGAR · Company announcement
GILD: Financial results
Filed 8-K for an event or period dated 2026-10-29. Financial results.
Follow GILD- Became public
- Oct 29, 2026, 4:03 PM EDT
- Event / period date
- Oct 29, 2026
- Collected
- Nov 7, 2026, 7:16 PM EST
Why this is connected
This filing identifies GILEAD SCIENCES, INC. as the issuer of the security. The company's SEC identifier connects it to GILD.
Press Release, issued by Gilead Sciences, Inc. on October 29, 2026 ↗Press Release, issued by Gilead Sciences, Inc. on October 29, 2026 ↗Source evidence
Read the source excerpt or record
Item 2.02 Results of Operations and Financial Condition. On October 29, 2026 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), announced its financial results for the quarter ended September 30, 2026. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 10, 11, 12 and 13 of the press release filed as Exhibit 99.1 to this report. The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on October 29, 2026 104 C
Congressional trading in GILD
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026
- Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026 · Dependent
- Feb 26, 2026$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Jan 27, 2026 · disclosed Feb 26, 2026 · Joint
- Oct 10, 2025$1K–$15K
Rep. Val T. Hoyle (D-OR-4)
$1K–$15K · Traded Sep 23, 2025 · disclosed Oct 10, 2025 · Spouse
- Sep 12, 2025$1K–$15K
Rep. Val T. Hoyle (D-OR-4)
$1K–$15K · Traded Oct 29, 2024 · disclosed Sep 12, 2025 · Spouse · filed 318 days later
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 18, 2025$1K–$15K
Rep. Marjorie Taylor Greene (R-GA-14)
$1K–$15K · Traded Jun 6, 2025 · disclosed Jun 18, 2025
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.